The total RNAi therapy market is estimated to value $580m by 2012. This forecast is based upon current treatments, levels of market satisfaction and five new Phase II/III RNAi agents profiled in this report.

This report provides a comprehensive review of nanotechnology and it’s role in the development of next-generation nanomedicines.

The purpose of this report is to describe the specific market segments of the medical research space using stem cells for research and development (R&D) purposes.

A complete and systematic description of the past, present and future efforts in cancer R&D focused on the vascular targeting field.

In this publication, BioSeeker Group analyzes the latest progress made for 25 drug candidates targeting the cell death pathway, apoptosis. Additionally, more early stage candidates are also under investigation, which brings the total number of compani

An update on the most recent advances made for vascular targeting agents that are now entering an exciting stage of development.

The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents.

There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 20 years ago. Many of the new classes of agents....

The DNA/RNA market is in its infancy with no significant products launched across the seven major markets. Despite the unproven nature of the sector in terms of market potential, it is commanding considerable interest across the biotechnology industry.

The targeted therapies market is relatively new in comparison to the cytotoxic and anti-hormonal therapies markets, and will therefore continue to show double-figure growth across the seven major pharmaceutical markets to 2014. Despite products which h

While the human genome project has provided vast amounts of sequence information, the in vivo functional analysis of thousands of genes has presented a significant challenge to researchers and to pharmaceutical companies in the discovery of new drug ta

There are today more than 380 protein kinase inhibitors for the treatment of cancer, from early preclinical to marketed drugs. Protein Kinase Inhibitors in Oncology: Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of

Peripheral artery disease (PAD) is the narrowing of the peripheral arteries that results from the build-up of plaque. The prevalence of peripheral artery disease is forecast to increase to 23m by 2012, as physicians become more aware of the disease and

A convergence of scientific advances has enabled the identification of molecular targets specific to cancer cells, resulting in therapies with enhanced selectivity, efficacy and reduced toxicity. Developers can rise to the clinical, regulatory and econ

A strategic outlook on protein kinase inhibitors in oncology. Including targets, indictions and competitive assessment.

Despite being the most common cause of death from gynecological tumors, ovarian cancer has not traditionally attracted the same level of R&D interest as other female cancers. Nevertheless, nearly 60,000 cases of ovarian cancer being diagnosed in the se